Sector News

Biogen announces billion-franc drugs plant

July 1, 2015
Life sciences
Biogen, an international biotechnology company, announced on Tuesday plans to invest one billion francs ($1.06 billion) for a new drug manufacturing plant in Luterbach in the canton of Solothurn.
 
The company told a press conference with officials from the canton that work would begin on the plant at the end of this year with completion set for the end of 2018.
 
By 2019 the plant should be operational, creating 400 jobs and producing biopharmaceutical medicine, Biogen said.
 
The plant would be the fifth for the company in the world.
 
Founded in 1978 by a group of biologists in Geneva, the company has grown to employ 7,500 people with operations in 30 countries and annual revenues of $5 billion.
 
With corporate headquarters in Massachusetts and international headquarters in the canton of Zug, the company says it is committed to discovering, developing and delivering therapies to patients with neurodegenerative diseases, autoimmune disorders and hemophilia, according to its website.
 
Biogen said it has several new drugs in the pipeline that have created the need for additional production capacity.
 
“Thanks to excellent support from the canton of Solothurn, the municipality of Luterbach and the federal government, we have the opportunity to build the most advanced production facilities in the world,” Natascha Schill, CEO of Biogen Switzerland, said in a statement.
 
She said Solothurn “offers a business-friendly environment, reliable infrastructure, and access to well-trained labour.”
 
As well, Schill noted that Biogen already had its international headquarters in Switzerland.
 
“All these factors contribute to the fact that we want to expand our global production network in Luterbach.” 
 
The canton of Solothurn said a preliminary agreement had been signed with Biogen.
 
But it said a period of public consultation was needed, with a municipal meeting planned later this week to gather feedback.
 
Interpharma, the association of research-based pharmaceutical companies in Switzerland, welcomed Biogen’s announcement.
 
It is a clear sign of the “attractiveness of Switzerland” as a location for the pharmaceutical industry, Interpharma spokesman Thomas Cueni is quoted as saying by the Tages Anzeiger newspaper.
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend